{"id":1009606,"date":"2026-10-13T11:05:04","date_gmt":"2026-10-13T15:05:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/scienture-reports-approximately-1-22-million-in-unaudited-preliminary-q3-2026-revenue-achieving-256-sequential-growth\/"},"modified":"2026-10-13T11:05:04","modified_gmt":"2026-10-13T15:05:04","slug":"scienture-reports-approximately-1-22-million-in-unaudited-preliminary-q3-2026-revenue-achieving-256-sequential-growth","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/scienture-reports-approximately-1-22-million-in-unaudited-preliminary-q3-2026-revenue-achieving-256-sequential-growth\/","title":{"rendered":"SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth"},"content":{"rendered":"
\n

\n Continued Arbli<\/b>
\n
\n \u2122<\/b>
\n <\/sup>
\n sales growth, combined with REZENOPY<\/b>
\n
\n \u2122<\/b>
\n <\/sup>
\n commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth<\/b>\n <\/p>\n

\n Arbli<\/b>
\n
\n \u2122<\/b>
\n <\/sup>
\n wholesale unit sales increased 74% sequentially, with recent institutional formulary additions supporting continued commercial expansion<\/b>\n <\/p>\n

\n COMMACK, NY, Oct. 13, 2026 (GLOBE NEWSWIRE) — <\/b>
\n SCIENTURE HOLDINGS, INC.<\/b>
\n (NASDAQ: SCNX) (\u201cScienture\u201d), <\/b>a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced preliminary, unaudited revenue of approximately $1.22 million for the third quarter ended September 30, 2026, representing an increase of 256% compared to approximately $344,000 in the second quarter of 2026.<\/p>\n

The substantial sequential increase in preliminary revenue reflects the successful commercial launch of REZENOPY\u2122<\/sup> and initial wholesale shipments, as well as continued sales growth and increasing market adoption of Arbli\u2122<\/sup>. These results mark an important milestone in Scienture\u2019s commercial expansion, reflecting the addition of a second FDA-approved product and continued progress toward building a diversified, multi-product pharmaceutical portfolio.<\/p>\n

\u201cThese preliminary third-quarter revenue results mark a significant inflection point for Scienture, demonstrating the accelerating commercial momentum of our expanding pharmaceutical portfolio,\u201d said Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings. \u201cWith Arbli\u2122<\/sup> continuing to gain traction and REZENOPY\u2122<\/sup> becoming our second commercial-stage product following its August 2026 launch, we believe Scienture is well-positioned to meaningfully accelerate top-line revenue growth through the remainder of 2026 and into 2027. As we work to expand our distribution channels and drive commercial adoption, we believe our historically high gross margins will provide significant operating leverage, supporting our goal of achieving profitability in 2027.\u201d<\/p>\n

\u201cOur preliminary third-quarter revenues reflect the progress we have made in executing our commercial strategy and establishing Scienture as a growing specialty pharmaceutical company,\u201d said Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture Holdings. \u201cLooking ahead, we see significant opportunities to further penetrate our addressable markets, particularly as we focus on increasing institutional adoption, expanding healthcare provider engagement and entering strategic commercial partnerships. With two differentiated FDA-approved products addressing important unmet needs commercialized, we believe Scienture is well-positioned to build a sustainable, high-value pharmaceutical business and deliver long-term value to shareholders.\u201d<\/p>\n

The preliminary revenue figures described in this press release are unaudited and subject to customary adjustments. The Company\u2019s full financial results for Q3 2026 will be included in a Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission in accordance with federal securities rules and regulations.<\/p>\n

\n About Arbli<\/b>
\n
\n \u2122<\/b>
\n <\/sup>\n <\/p>\n

Arbli\u2122<\/sup> is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli\u2122<\/sup> is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli\u2122<\/sup> provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli\u2122<\/sup> provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli\u2122<\/sup> has two issued patents from the USPTO, which are also listed in the FDA Orangebook.<\/p>\n

Arbli\u2122 is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli\u2122<\/sup> comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for\u00a0a shelf life of 24 months from the date of manufacture when stored at room temperature.<\/p>\n

\n INDICATION<\/b>\n <\/p>\n

Arbli\u2122<\/sup> is an angiotensin II receptor blocker (ARB) indicated for:<\/p>\n